Skin protein K16 found to control inflammation in stressed skin
medicalxpress - Keratin is the fibrous, waterproof protein that builds everything from our hair and nails to a rhino's horn. However, a tiny glitch in it can have problematic outcomes. A new study has found that changes in a keratin gene called KRT16 can lead to a rare c…
AI Summary: Researchers identified keratin 16 (K16) as a molecular brake on skin inflammation: loss of K16 ramps up interferon-driven immune signals, while its presence calms stressed keratinocytes. The discovery points to new targets for inflammatory skin disorders and suggests modulating K16 pathways could yield therapies that actually treat inflammation, not just slap on a cream.
Gilead continues dealmaking streak with $3.15B Tubulis buy for ADCs
Kyle LaHucik / endpoints - In its third acquisition of 2026, Gilead is spending $3.15 billion upfront to snag a next-generation antibody-drug conjugate platform from German startup Tubulis. The California biopharma could pay out another $1.85 billion down the road ...
AI Summary: Gilead Sciences struck a multibillion-dollar acquisition to add Tubulis and bolster its oncology pipeline, buying into antibody-drug conjugate technology. The deal signals Gilead’s strategic pivot to expand beyond infectious disease into cancer therapeutics, accelerating access to novel modalities and reshaping competitive dynamics in biopharma.
AbbVie sues HHS over 340B patient definition
Ella Jeffries / beckershospitalreview - AbbVie has filed a lawsuit challenging federal guidance on how “patient” is defined under the 340B program, according to an April 8 press release. The company said the current definition, based on guidance issued in 1996, allows covered entities to claim …
AI Summary: AbbVie has filed suit challenging HHS’s interpretation of the 340B program, arguing the agency’s “patient” definition and related guidance are outdated and legally flawed. The company seeks judicial clarity that could reshape who qualifies for discounted drugs and how hospitals and manufacturers navigate the program — yes, the pricing drama continues.
RFK Jr. launching health podcast to expose ‘hypocrisy’ and ‘corruption’
fiercehealthcare - Robert F. Kennedy Jr. is starting a podcast. Unveiling the show on social media, the Department of Health and Human Services (HHS) secretary framed the podcast as a response to public health problems that he said have made “many of us ... come to the conc…
AI Summary: Robert F. Kennedy Jr. is debuting a health-focused podcast promising to call out what he characterizes as hypocrisy and corruption in medicine and public health. The show aims to amplify skeptical takes on mainstream health institutions and policies, positioning itself as a combative platform for contrarian voices and investigations.
HHS updates vaccine panel requirements after judge's decision
medicalxpress - Health officials are changing the rules for who can serve on a key vaccine advisory panel after a judge ruled that many current members are unqualified.
AI Summary: Following a court decision, HHS has revised vaccine advisory committee requirements and the CDC is moving forward with changes to its vaccine advisory structure. Federal agencies are retooling membership and operating rules to restore advisory functions while navigating legal limits, aiming to keep vaccine guidance intact — whether the courtroom likes it or not.
- CDC delays vaccine-effectiveness reports; vaccine-priority lessons examined (4)
- Courts and states press legal challenge to HHS restructuring (4)
- HHS reconstitutes vaccine advisory panel under new charter and appointments (2)
- Kennedy-driven shake-up amplifies vaccine-safety focus and skepticism voices (2)
- All Other Stories
CDC delays vaccine-effectiveness reports; vaccine-priority lessons examined
Courts and states press legal challenge to HHS restructuring
HHS reconstitutes vaccine advisory panel under new charter and appointments
Kennedy-driven shake-up amplifies vaccine-safety focus and skepticism voices
All Other Stories
Digital health startups raked in $4B during Q1 with 12 megadeals driving investment: Rock Health
fiercehealthcare - Digital health startups pocketed $4 billion in venture capital funding in the first quarter of 2026, marking the strongest first quarter since the pandemic peak.
AI Summary: Venture investment in digital health is narrowing: a small number of startups captured a large share of Q1 funding, driven by a handful of megadeals. The trend signals investor preference for later‑stage companies and scale plays, squeezing early innovators who must now demonstrate clearer paths to durable revenue and clinical impact.
Disruption expected as six-day doctors' strike begins
bbc - The NHS is advising patients in England to only use emergency services when necessary but attend any confirmed appointments.
AI Summary: A coordinated six‑day doctors' strike has caused significant disruption across hospitals and clinics, leading to postponed appointments, diverted emergency visits and heightened anxiety among patients awaiting care. Health leaders urge targeted communication and contingency staffing while negotiators and striking doctors trade barbs — and patients try not to become collateral damage.
- Cancellations provoke fury as doctors warn of staffing crisis (3)
- Healthcare labour unrest: unions, petitions and declining staff morale (3)
- NHS urges patients: attend confirmed appointments, avoid A&E (3)
- Other: research inclusion debate and volatile crypto markets (3)
- All Other Stories
Cancellations provoke fury as doctors warn of staffing crisis
Healthcare labour unrest: unions, petitions and declining staff morale
NHS urges patients: attend confirmed appointments, avoid A&E
Other: research inclusion debate and volatile crypto markets
All Other Stories
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B to Expand Rare Disease Portfolio
oncodaily - Neurocrine Biosciences has entered into a definitive agreement to acquire Soleno Therapeutics, marking a strategic expansion into rare disease treatments and strengthening its late-stage pipeline. The deal signals continued consolidation […]
AI Summary: Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $2.9 billion, picking up Soleno’s Prader‑Willi treatment candidate and bolstering its rare‑disease portfolio. The purchase folds Soleno’s clinical assets and research teams into Neurocrine, positioning the buyer to commercialize a potential high‑value therapy while shoring up long‑term pipeline growth.
Can a single therapy session make a difference? Yes, with the right mindset
abcnews - Can a single therapy session make a difference
AI Summary: Experts report that a single, well‑structured therapy session can produce meaningful short‑term benefits for some patients when expectations, mindset, and therapeutic focus align. It’s not a miracle cure, but the finding nudges clinicians and policymakers toward pragmatic, low‑burden interventions that can provide rapid relief while longer‑term care is arranged.
Rabi Hanna: First-in-Human CRISPR/Cas12a Therapy in Sickle Cell Disease
oncodaily - Rabi Hanna, Pediatric Blood and Marrow Transplant Program Director, and Chairman at the Department of Pediatric Hematology-Oncology and BMT at Cleveland Clinic, shared a post on LinkedIn: “I am excited […]
AI Summary: A first‑in‑human CRISPR/Cas12a therapy for sickle cell disease has treated initial patients, building on preclinical gene‑editing successes that reversed severe disease in models. The advance underscores rapid translation from lab to clinic and renews hope for durable cures—while reminding everyone that the safety and long‑term durability questions remain firmly on the table.
Uveal Melanoma: ESMO–EURACAN Clinical Practice Guideline
esmo - This ESMO–EURACAN CPG provides key recommendations for the diagnosis, staging, treatment and follow-up for uveal melanoma. It includes percutaneous hepatic perfusion and tebentafusp as treatment options for metastatic disease, reflecting emerging evidence…
AI Summary: ESMO–EURACAN released a comprehensive clinical practice guideline for uveal melanoma covering diagnosis, staging, surveillance and systemic management. The guidance clarifies best practices for multidisciplinary care, risk stratification and therapeutic sequencing, aiming to standardize treatment and follow‑up for a rare but high‑risk ocular tumour.
CHS sells 180-bed hospital for $459M: 6 things to know
Alan Condon / beckershospitalreview - Franklin, Tenn.-based Community Health Systems on April 1 sold Crestwood Medical Center — a 180-bed hospital in Huntsville, Ala. — to Huntsville Hospital Health System for $459 million. Six things to know: 1. The deal includes all of the assets tied to th…
AI Summary: Community Health Systems has finalized the sale of a 180‑bed Alabama hospital for $459 million, concluding a transaction that reshuffles local care ownership and may prompt operational changes. The closing marks a notable consolidation step in regional hospital markets and raises questions about continuity and access as the new owner assumes control.
Bowelbabe Fund celebrates raising £20m by announcing the Bowelbabe Vaccine
Sophie Wedekind / cancerresearchuk - The Bowelbabe Fund has raised more that £20 million and has announced the next wave of funded projects, including the Bowelbabe Vaccine.The post Bowelbabe Fund celebrates raising £20m by announcing the Bowelbabe Vaccine appeared first on Cancer Research U…
AI Summary: The Bowelbabe Fund celebrated a £20 million fundraising milestone and unveiled plans for a Bowelbabe Vaccine initiative, drawing high‑profile support. Organizers framed the cash infusion as a catalyst for prevention and research efforts, while public endorsements highlighted momentum — and the fundraising thermometer that finally stopped making them blush.
Targeted, High-dose Radiation May Improve Treatment for ‘Supermassive’ Bile Duct Tumors
Kathleen Medora / aacr - Patients with very large intrahepatic cholangiocarcinoma experienced improved outcomes when targeted, high-dose radiation was added to chemotherapy PHILADELPHIA – Patients with supermassive intrahepatic cholangiocarcinoma (ICC) benefited from ablative rad…
AI Summary: New clinical reports indicate that targeted high‑dose radiation can improve outcomes for very large “supermassive” bile duct tumors, offering better local control and symptom relief than conventional approaches. Early data suggest this intensity‑modulated strategy may expand options for otherwise difficult‑to‑treat cases, though longer follow‑up is needed to confirm survival benefits.
FDA identifies eight deaths tied to Amgen's Tavneos
Max Bayer / endpoints - The FDA on Tuesday flagged more than 70 cases of severe liver injury and eight deaths associated with Amgen’s autoimmune treatment Tavneos, but the company said it previously notified the agency about the risk of ...
AI Summary: The FDA has tied eight patient deaths to Amgen’s drug Tavneos, prompting heightened regulatory review and industry concern. Reports outline safety signals and agency actions as clinicians and manufacturers reassess risk‑benefit profiles, while regulators weigh labeling, monitoring or other interventions to protect patients.
Biogen to acquire Apellis for $5.6B
Elizabeth Cairns / endpoints - Biogen has made a $5.6 billion deal to acquire Apellis Pharmaceuticals, the companies announced Tuesday. The deal will allow Biogen to get hold of the kidney disease drug Empaveli and the eye disease therapy Syfovre ...
AI Summary: Biogen agreed to acquire Apellis Pharmaceuticals for $5.6 billion, a deal pitched as a strategic move to broaden Biogen’s pipeline and bolster its biopharma foothold. Analysts and company spokespeople framed the purchase as value‑accretive, even as skeptics question integration risks and the price tag in a cautious market.
Memorial Hermann goes out of network with BCBS Texas
Elizabeth Casolo / beckershospitalreview - Houston-based Memorial Hermann Health System’s contract with BCBS Texas expired April 1, rendering the health system out of network. Commercial and ACA exchange (both individual and family) plan members lost access at the end of March. Memorial Hermann ha…
AI Summary: Memorial Hermann and Blue Cross Blue Shield of Texas failed to agree on a new contract, resulting in the health system going out of network for affected plan members. Patients face potential higher costs and care disruptions while negotiators jockey publicly; both sides warn of financial stakes and urge members to stay informed.
White House floats 12.5% budget cut for HHS in FY2027, reiterates reorganization plan
fiercehealthcare - The requested budget cut is about half of what the administration asked, and was denied, last year. However, plans for reorganizing agencies under an Administration for a Healthy America persist, as do calls to eliminate various programs and centers the W…
AI Summary: The administration has floated a plan to cut HHS funding by roughly 12–12.5% in FY2027 while pursuing agency reorganization. The proposal targets discretionary programs including research funding, prompting scientific groups to urge Congress to reject the NIH reductions and warn of downstream impacts on biomedical research and patient care.
- Researchers, cancer groups warn NIH cuts will harm patients (6)
- White House pushes deep HHS cuts, agency reorganization (4)
- All Other Stories
Researchers, cancer groups warn NIH cuts will harm patients
White House pushes deep HHS cuts, agency reorganization
All Other Stories
Why 131 Hospitals Are Suing HHS Over Alleged Underpayment
Katie Adams / medcitynews - A group of 131 hospitals has sued HHS over a CMS policy they say improperly reduces Medicare disproportionate share hospital (DSH) payments. The lawsuit is the latest in a decade-long legal battle over how the agency counts patient days and calculates pay…
AI Summary: One hundred thirty‑one hospitals have filed suit challenging HHS’s 2023 Disproportionate Share Hospital calculation, arguing the agency’s formula undercounts uncompensated care and systematically underpays safety‑net providers. The plaintiffs seek to overturn the rule and recover alleged shortfalls, warning that ongoing underpayment threatens hospital finances and patient access.
CMS finalizes Medicare Advantage star ratings overhaul, sending billions of dollars more to insurers
Rebecca Pifer Parduhn / healthcaredive - Regulators cut almost a dozen metrics that factor into the quality ratings and reverted back to an older and more generous bonus system. MA plans will get more than $18 billion in additional payments over the next decade as a result.
AI Summary: The Centers for Medicare & Medicaid Services locked in a sweeping overhaul of Medicare Advantage star ratings that will shift billions of dollars in payments and alter plan incentives. The ruling adjusts rating calculations and enrollment provisions, prompting industry and provider concerns about downstream effects on access, plan behavior, and provider-network stability.